Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Investors Wary Of In-Licensing-Only Biotechs After IPO Setback

Executive Summary

The torpedoed IPO application of a Shanghai-based biotech has already triggered a ripple of unease among venture capitalists in China, with some signaling suspension of investment in similar ventures.

You may also be interested in...



Gilead Summits Takeback Of Trodelvy Rights In Deal With Everest

Deal Snapshot: Through subsidiary Immunomedics, Gilead will pay $280m up front to gain the remaining global rights to the drug, at a time when Everest’s business model has encountered some difficulties in China.

2021 Marked New Era Of Domestic Collaboration in China

Major deals showed an increasing focus on domestic tie-ups while an unsatiable appetite for innovation drove drug firms to actively seek out biotechs for collaboration.

LianBio Gets Chinese Biotech US IPOs Rolling Again But Followers Scant

Billed as BridgeBio in China, US-based and China-oriented biotech LianBio breaks a long hiatus in US listing for Chinese biotechs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel